WHO ICTRP trial
Study A: A placebo-controlled crossover study to assess safety of intranasal…
NL-OMON55390 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON55390 |
|---|---|
| Public title | Study A: A placebo-controlled crossover study to assess safety of intranasal administration of palivizumab Study B: Effect of intranasal administration of palivizumab on respiratory syncytial virus-associated infection - a double-blind randomized controlled trial |
| Scientific title | Study A: A placebo-controlled crossover study to assess safety of intranasal administration of palivizumab Study B: Effect of intranasal administration of palivizumab on respiratory syncytial virus-associated infection - a double-blind randomized controlled trial - Narsyn: Nasal administration of… |
| Primary sponsor | Universitair Medisch Centrum Utrecht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Netherlands |
| Conditions | bronchiolitis RSV respiratory tract infection;10047438;10024970 |
| Interventions | Study A: 1 nose drop in the right nostril once daily of 1 mg/mL palivizumab or placebo for 7 days; 14 day washout period, then crossover to other arm for 7 days. Study B: 1 nose drop per nostril once daily of 1 mg/mL palivizumab or placebo… |
| Registration date | Aug 15, 2018 |
| Target size | 408 |
| Secondary IDs | 2018-002742-37;NL66735.041.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: